USFDA approves breakthrough drug for hepatitis C

The U.S. has approved a breakthrough therapy for treatment of chronic hepatitis C that is expected to offer a more palatable cure to millions of people infected with the liver-destroying viral disease.
Approved by the Food and Drug Administration, the pill, Sovaldi (sofosbuvir) is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon, an official announcement said on Friday.
“Today’s (Friday’s) approval represents a significant shift in the treatment paradigm for some patients with chronic hepatitis C,” said Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research.
Sovaldi is the second drug approved by the FDA in the past two weeks to treat chronic HCV (hepatitis C virus) infection.
On November 22, the FDA had approved Olysio (simeprevir).
Sovaldi is marketed by Gilead, based in Foster City, California. Olysio is marketed by Raritan, New Jersey-based Janssen Pharmaceuticals.
Clinical trials

The FDA said Sovaldi’s effectiveness was evaluated in six clinical trials consisting of 1,947 participants, who had not previously received treatment for their disease (treatment-naive) or had not responded to previous treatment (treatment-experienced), including participants co-infected with HCV and HIV.

Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.
About 3.2 million Americans are infected with hepatitis C, according to the Centers for Disease Control and Prevention, the CNN said.
Symptoms

Symptoms may include fever, fatigue, loss of appetite, vomiting, nausea, abdominal pain, dark urine, clay—coloured bowel movements, joint pain and jaundice, according to the CDC.

The once-a-day pill is the first approved to treat certain types of hepatitis C infection without the need for interferon, an injected drug that can cause severe flu-like symptoms. Hepatitis C, which is often undiagnosed, affects about 3.2 million Americans, killing more than 15,000 each year, mostly from illnesses such as cirrhosis and liver cancer. Most patients will be treated with the $1,000-a-day drug for 12 weeks, resulting in a total list price of $84,000, according to Gilead spokeswoman Cara Miller.
Last year, the CDC recommended that all baby boomers, born from 1945 to 1965, be tested for the virus. Introduction of blood and organ screening in the 1990s has dramatically lowered infection rates for younger generations.
The Gilead drug's approval was supported by several studies showing that it helped to eradicate the virus in significantly more patients, with fewer side effects, than the current drug regimen.
Sovaldi is the first in a new class of medications known as nucleotide analogue inhibitors, or "nukes," designed to block a specific protein that the hepatitis C virus needs to copy itself.

Popular posts from this blog

PG Doctors of India must work not more than 48 Hr/week: SC

Image
As per the directives of the Honourable Supreme Court in its judgment dated,25.9.87, in writ petition No. 348-352 of 1985, all the State Governments, Medical Institutions and Universities are required to amend their rules and regulations to introduce a uniform residency scheme by 1993 “A uniform practice has to be evolved so that the discipline would be introduced. We accordingly allow the present arrangement to continue for a period of five yearsI.e. upto 1992 inclusive. For admission beginning from 1993 there would be only onepattern. All Universities and institutions shall take timely steps to bring about such amendments as may be necessary to bring statutes, regulations, and rules obtaining in their respective institutions in accord with this direction before the end of 1991 so that there may be no scope for raising of any dispute in regard to the matter.The uniform pattern has to be implemented for 1993. It is proper that one uniform system is brought into vogue throughout
Read more

Why DNB exam tougher than MS/MD exam?

Image
Guest article by Dr Kalyan R Kone   There were 6 people (accompanied by their relatives) sitting in the small waiting room outside the ward waiting for their call inside. They looked battered, tense and had such a depressed look in their eyes that even Shylock would have sympathized with them. They had cleared their DNB (Diplomate of National Board) theory exam and were making last minute preparations for their practical exam. If I were not told that they were all Doctors, I would have thought that they were all waiting for their turn to see a psychiatrist. Dr Kalyan R Kone Five out of six of those waiting doctors were appearing for the second or third time. In spite of that, they didn’t know what would be in store for them except one thing — only one or two would pass out of the six candidates. I thought for a moment that it was a good ploy by the NBE (National Board of Examination) to generate funds – after all, where would these poor guys go except appe
Read more